Loading...
Market
Will the merger between Recursion Pharmaceuticals and Exscientia receive regulatory approval by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from regulatory authorities such as the SEC or FTC, official press releases from either company
Story
Recursion and Exscientia to Merge in $688 Million All-Stock Deal
Aug 8, 2024, 12:02 PM
Recursion Pharmaceuticals and Exscientia have entered a definitive agreement to merge, creating a global leader in technology-enabled drug discovery. The merger, valued at $688 million, is an all-stock deal that will combine Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The collaboration is expected to enhance the companies' end-to-end capabilities in the biotech sector, marking a significant milestone in the use of AI in drug development.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%